Pharma Pricing & Market Access Europe 2011

8am Registration & coffee

8.45am Opening remarks from the chair

9am Policy challenges in market access for pharmaceuticals in Europe
·         Key economic developments in Europe and their impact on pricing policy
·         New pricing or partnering models being considered or introduced
·         How will the drugs industry respond to these challenges?
Dr Andrea Rappagliosi,Vice President Corporate Relations, GlaxoSmithKline

FOCUS ON USA

9.25am Maneuvering changes in the U.S. health care environment
·         Impact of health care reform today
·         Comparative effectiveness research
·         Changes in co-pay and co-insurance
·         Role of coupons and co-pay offsets
·         Implications for price optimization
Mr Ed Schoonveld,Principal, ZS Associates

9.55am Keynote address: US healthcare reform and it impact on market access
·         The sky is falling! Or is it? Either way you must now deal with: The Good (what works), The Bad (what doesn’t work) and The Ugly (what we don’t know).
·         Healthcare enterprise participants must now deal with the dilemmas posed by the ugly, and create a discipline around: accountability, but by whom, for what (knowledge, actions, or outcomes), to whom, and when? Why bother? Is it now irrelevant?
·         Or is it, at long last, refocused on: the oft forgotten and forlorn object of this all: our patient and her clinical and economic wellbeing.
Dr Allan Korn,Senior Vice President, Chief Medical Officer, Blue Cross Blue Shield Association

10.20am Pharmaceutical Industry Perspective
Mr James Scott,-, Applied Policy

11.05am Speed Networking & Morning Refreshments

 POLICY UPDATES - NORTHERN EUROPE

11.45am The Role of NICE in the new healthcare environment
·         Overview of the major policy developments that impact technology appraisals
·         What is the NICE role in the proposed changes to the drugs approval process
·         How is NICE adapting to the new priorities in both industry and in public health?
Meindert Boysen,Associate Director, NICE

12.10pm Emerging views of a future value based pricing system for the UK
·         Determining value – how do you do it?
·         Managing the transition from the current PPRS to value based pricing
·         How can industry and payers work together to ensure that the best treatments make it to the patient?
Dr Paul Catchpole,Value and Access Director, ABPI

12.35pm France: Latest Developments in Pricing and Reimbursement Policy
·         Drug pricing in France – the rules
·         HAS’s policy on access to innovative treatments
·         The role of HTA in the pricing and reimbursement decision making process
·         New developments that reflect the current economic environment
Prof Lise Rochaix,Member of the Board, HAS

1pm Lunch

 FOCUS ON CANADA

2pm Canada: The Evolving P&R Environment
·         Overview of Canadian P&R, market access
·         Impact of the 2010 changes to the PMPRB price guidelines
·         HTA overview: CADTH/CDR, new HTA agencies pCODR, INESSS
·         Risk sharing, listing agreements and the evolving provincial reimbursement schemes
·         Implications of new generics policies on brand pricing and reimbursement
·         Outlook for P&R, market access in Canada
Mr Neil Palmer,Vice President, Pricing & Reimbursement, PDCI Market Access

2.25pm Cancer Drug Reimbursement in Canada: Focus on Ontario
·         Overview of the Ontario Cancer Care plan
·         Update on and trends in cancer drug utilisation
·         Case study of recent listing decisions
Mr Scott Gavura,Director, Provincial Drug Reimbursement Programs, Cancer Care Ontario

2.50pm Valuing New Medicines
·         Impact of the new funding environment.
·         Potential for new models of care
·         The new pressures US/Europe Asia
·         Which diseases/specialties will register most impact?
·         Is a new partnership possible--industry/patients/funders?
Prof Nick Bosanquet,Head of Health Policy, Imperial College

3.15pm Afternoon refreshments

 FOCUS ON GERMANY

3.45pm Germany: Latest Developments in Pricing and Reimbursement Policy
·         Role of G-BA in drug regulation in Germany
·         Upcoming changes: New law for drug regulation in Germany
·         Obligatory dossier on benefit and costs with market launch
·         Rapid and early assessment of all new drugs
·         The role of IQWiG in the decision making process
·         Consultations and meetings with manufacturers
·         Impact on patients, payers and industry
Dr Stefan Lange, Deputy Director, IQWiG, Germany (subject to final confirmation)
Dr Thomas Muller,Head of Pharmaceuticals, GBA
Dr Rainer Walenta,Director, Global Pricing & Reimbursement, Abbott Products GmbH

4.45pm Italy: Latest Developments in Pricing and Reimbursement policy
·         Access to medicines in Italy under the NHS
·         Criteria for pricing and reimbursement
·         Governance of pharmaceutical expenditure
·         Experiences with risk sharing and conditional reimbursement
Dr Pietro Folino Gallo,Head of Osmed Unit, AIFA

5.10pm Panel discussion

5.40pm Closing remarks

5.45pm The evening drinks reception is an opportunity to relax and network over drinks with conference attendees.

6.45pm End of day one  


Day Two Thursday 24 March 2011

Pascal Apostolides, General Manager, Abbott Laboratories Hellas SA

Prof Federico Augustovski, Director of Health Economic Evaluations and Technology Assessment, Institute for Clinical Effectiveness and Health Policy

Maria Avxentyeva, Deputy Director, Research Institute of Clinico-economic Expertise and Pharmacoeconomics, Russian State Medical University

Prof Nick Bosanquet, Head of Health Policy, Imperial College

Meindert Boysen, Associate Director, NICE

Martin Brown, Head of Health Economics and Outcomes Research, Novartis Pharmaceuticals UK Limited

Dr Paul Catchpole, Value and Access Director, ABPI

Ms Helga Festøy, Head of Section, Norwegian Medicines Agency

Dr Pietro Folino Gallo, Head of Osmed Unit, AIFA

Mr Jim Furniss, Director, Global Market Access, Bridgehead International Ltd

Mr Scott Gavura, Director, Provincial Drug Reimbursement Programs, Cancer Care Ontario

Dr Allan Korn, Senior Vice President, Chief Medical Officer, Blue Cross Blue Shield Association

Wim Leereveld, Founder & Chair, Access to Medicines Index

Dr Thomas Muller, Head of Pharmaceuticals, GBAMr Neil Palmer, Vice President, Pricing & Reimbursement, PDCI Market Access

Dr Andrea Rappagliosi, Vice President Corporate Relations, GlaxoSmithKline

Prof Lise Rochaix, Member of the Board, HAS

Toros Sahin, Pricing and Reimbursement Coordinator, Sanofi-Aventis

Mr Ed Schoonveld, Principal, ZS Associates

Mr James Scott, President and CEO, Applied Policy

Dr Martin van der Graaff, Secretary, Reimbursement Committee, CVZ

Dr Rainer Walenta, Director, Global Pricing & Reimbursement, Abbott Products GmbH

Ziyan Wang, Senior PRA Manager, Eli Lilly Asia

Colin Wight, Chief Executive, GalbraithWight